Last checked at 25 Sep 2014 09:58
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Proteome Share News (PRM)
PRM Share
Price
PRM Share
News
PRM Share
Chat
PRM Share
Trades
PRM
Live RNS
PRM Share
Charts
PRM Level 2
Console
PRM Live
Share Price
PRM Broker
Ratings
PRM Directors
Deals
PRM Financial
Diary
PRM
Fundamentals
PRM Short
Positions
PRM
Media
Proteome Information
Share Price Information for Proteome (PRM)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
4.00
Bid:
3.20
Ask:
4.80
Change:
0.00 (0.00%)
Spread:
1.60 (50.00%)
Open:
0.00
High:
0.00
Low:
0.00
Prev. Close:
4.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Proteome stroke test could save thousands from brain damage
Tue, 18th Sep 2012 10:57
Medical technology group Proteome Sciences has released details of a study into a blood test which could reduce brain damage in thousands of stroke victims.The group has been collaborating with researchers at the University of Geneva to produce the test which can tell how long ago a stroke actually took place. The exact timing of a stroke has a big influence on the kind of therapy that is used to help patients recover. Treated quickly, the brain damage caused by strokes can be significantly reduced, but as many strokes take place during sleep, it is often difficult to know when the symptoms began.During the study, scientists found one protein, known as GSTP, which showed an almost instantaneous increase in the blood of stroke patients, peaking at three hours after onset and returning to normal levels within around six hours.Extrapolating the results across patients who were admitted to the Geneva Hospital in 2006/7 with suspected stroke, but who did not know when their stroke symptoms started, indicates that testing for GSTP could result in as many as five times more people being eligible for the highly effective "rt-PA" treatment, which can only be used within 4.5 hours of a stroke under UK medical guidelines.The leader of the study, Professor Jean-Charles Sanchez, said: "This is a major step towards improving the management of ischaemic stroke patients using the drugs that we already have available. A simple blood test that matches the therapeutic window of rt-PA is a major advance."Dr Peter Coleman, Deputy Director of Research at The Stroke Association agreed, adding: "When a stroke strikes, time lost is brain lost, meaning that getting to hospital and receiving treatment quickly is absolutely essential. "A test such as this which could be used to quickly diagnose a stroke, possibly before a patient arrives at hospital, could speed up the treatment process and potentially improve outcomes."Proteome's share price rose 3.2% on Tuesday morning and has now gained 63% in the last 12 months.BS
More News
8 Jul 2014 11:19
8 Jul 2014 08:45
UPDATE 1-Study paves way for simple blood test to predict Alzheimer's
* Fatal brain-wasting disease has no effective treatments * Experts say drug failures may be due to late trials * Predictive test could find people before disease sets in * Shares in Proteome Sciences, involved in work, jump 12 pct (Adds Proteome Sciences stock move) By
Read more29 May 2014 10:22
Proteome Sciences Confident For Revenue Growth As Loss Narrows
LONDON (Alliance News) - Proteome Sciences PLC Thursday expressed confidence for continued fast revenue growth for the "forseeable future", as it posted a narrowed pretax loss for 2013, driven by strong sales of its Tandem Mass Tag reagents and growth in its biomarker assays. Proteome is en
Read more27 Mar 2014 14:08
Proteome Says Study Using SysQuant Technology Demonstrates Its Potential
LONDON (Alliance News) - Proteome Sciences PLC said Thursday that a study using its SysQuant technology to address pancreatic cancer published in medical journal PLOS ONE demonstrated the potential of proteomics to improve the way that bespoke treatments can be made to match patients. Prote
Read more28 Feb 2014 16:18
XP Power board members reduce holdings
XP Power's Chairman, Larry Tracey, on Thursday sold 75,000 shares in the power supply solutions manufacturer. Tracey, who has held his current role since April 2002, disposed of the shares at 1,755p a time, generating a total of £1.3m. Fellow board member James Peters, a Non-Executive Director, t
Read more24 Feb 2014 10:48
Proteome Sciences To Raise GBP5 Million In Share Placing
LONDON (Alliance News) - Proteome Sciences PLC said Monday it has placed 17.9 million new shares on the market to raise GBP5 million before expenses, with new and existing investors, which it will use for additional working capital. The protein biomarker company said the shares were placed
Read more7 Feb 2014 10:06
Proteome edges ahead after flagging rise in revenue
Biotech group Proteome Sciences edged ahead after it revealed it expects revenue for 2013 to show "a significant increase" over 2012 thanks to strong performance across its core activities. The firm is an expert in biomarkers, or biological markers, that can help predict the likelihood of cancer r
Read more7 Feb 2014 09:08
Proteome Sciences Says 2013 Revenues To Be Significantly Up
LONDON (Alliance News) - Shares in Proteome Sciences PLC rose in early trading Friday, after the protein biomarker company said revenue for 2013 will be significantly higher than the prior year, driven by a strong performance from all its core activities. Proteome is engaged in research an
Read more4 Dec 2013 10:39
Proteome Sciences unveils sales delays, shares fall
Biotechnology group Proteome Sciences is facing sales delays that will push revenue from some deals into next year, hitting its shares. Proteome, which carries out research into protein and peptide biomarkers to treat neurological conditions and other illnesses such as cancer, said the timing and r
Read more